

# David W Mullins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3661826/publications.pdf>

Version: 2024-02-01

50  
papers

2,611  
citations

218677

26  
h-index

189892

50  
g-index

51  
all docs

51  
docs citations

51  
times ranked

4044  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
2	Field Emergence in Civil Society: A Theoretical Framework and Its Application to Community-Led Housing Organisations in England. <i>Voluntas</i> , 2020, 31, 184-200.	1.7	9
3	A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. <i>International Journal of Cancer</i> , 2020, 146, 1409-1420.	5.1	22
4	Grassroots innovations in community-led housing in England: the role and evolution of intermediaries. <i>International Journal of Urban Sustainable Development</i> , 2020, 12, 52-72.	2.0	13
5	Distinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathology. <i>Scientific Reports</i> , 2020, 10, 5901.	3.3	2
6	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. <i>Frontiers in Medicine</i> , 2019, 6, 170.	2.6	6
7	LNK suppresses interferon signaling in melanoma. <i>Nature Communications</i> , 2019, 10, 2230.	12.8	21
8	Self-organised and civil society participation in housing provision. <i>International Journal of Housing Policy</i> , 2018, 18, 1-14.	1.8	39
9	Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy. <i>OncImmunology</i> , 2018, 7, e1398875.	4.6	16
10	Achieving policy recognition for community-based housing solutions: the case of self-help housing in England. <i>International Journal of Housing Policy</i> , 2018, 18, 143-155.	1.8	19
11	Beta-glucan-induced inflammatory monocytes mediate antitumor efficacy in the murine lung. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1731-1742.	4.2	24
12	Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. <i>Cancer Research</i> , 2017, 77, 1271-1282.	0.9	134
13	CXCR3+ monocytes/macrophages are required for establishment of pulmonary metastases. <i>Scientific Reports</i> , 2017, 7, 45593.	3.3	24
14	Adaptive immunity programmes in breast cancer. <i>Immunology</i> , 2017, 150, 25-34.	4.4	43
15	The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells. <i>Melanoma Research</i> , 2016, 26, 223-235.	1.2	22
16	Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1189-1199.	4.2	38
17	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1201-1212.	4.2	36
18	Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. <i>Nature Communications</i> , 2016, 7, 10248.	12.8	34

#	ARTICLE	IF	CITATIONS
19	Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-7.	1.5	10
20	The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. <i>Matrix Biology</i> , 2015, 48, 66-77.	3.6	19
21	Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease. <i>Cancer Immunology Research</i> , 2015, 3, 956-967.	3.4	33
22	CXCR3 Signaling in BRAFWT Melanoma Increases IL-8 Expression and Tumorigenicity. <i>PLoS ONE</i> , 2015, 10, e0121140.	2.5	16
23	Multiple murine BRAF <sup>V600E</sup> melanoma cell lines with sensitivity to PLX4032. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 495-501.	3.3	71
24	BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 1044-1050.	3.4	57
25	Differential expression and tumor necrosis factor- $\alpha$ -mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 571-579.	3.3	11
26	Immune-Mediated Regression of Established B16F10 Melanoma by Intratumoral Injection of Attenuated <i>Toxoplasma gondii</i> Protects against Rechallenge. <i>Journal of Immunology</i> , 2013, 190, 469-478.	0.8	98
27	Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. <i>Journal of Cellular Physiology</i> , 2013, 228, 773-780.	4.1	12
28	Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen-Specific CD8 T Cells. <i>Cancer Immunology Research</i> , 2013, 1, 332-339.	3.4	25
29	Scaling-up or going viral? Comparing self-help housing and community land trust facilitation. <i>Voluntary Sector Review</i> , 2013, 4, 333-353.	0.4	21
30	Extracellular Hepatitis C Virus Core Protein Activates STAT3 in Human Monocytes/Macrophages/Dendritic Cells via an IL-6 Autocrine Pathway. <i>Journal of Biological Chemistry</i> , 2011, 286, 10847-10855.	3.4	82
31	Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2010, 33, 965-974.	2.4	56
32	The Protein Tyrosine Phosphatase SHP-1 Modulates the Suppressive Activity of Regulatory T Cells. <i>Journal of Immunology</i> , 2010, 185, 6115-6127.	0.8	32
33	Immunity to Melanoma Antigens: From Self-Tolerance to Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 243-295.	2.2	55
34	Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel $\beta$ 2-Microglobulin Loss-of-function in Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 18763-18773.	3.4	53
35	Limited Infiltration of Exogenous Dendritic Cells and Naive T Cells Restricts Immune Responses in Peripheral Lymph Nodes. <i>Journal of Immunology</i> , 2006, 176, 4535-4542.	0.8	19
36	Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma. <i>Journal of Immunology</i> , 2005, 174, 6863-6871.	0.8	91

#	ARTICLE	IF	CITATIONS
37	CXC Chemokine Receptor 3 Expression by Activated CD8+ T cells Is Associated with Survival in Melanoma Patients with Stage III Disease. <i>Cancer Research</i> , 2004, 64, 7697-7701.	0.9	127
38	Antigen Density Presented By Dendritic Cells In Vivo Differentially Affects the Number and Avidity of Primary, Memory, and Recall CD8+ T Cells. <i>Journal of Immunology</i> , 2003, 170, 1822-1829.	0.8	116
39	Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control. <i>Journal of Experimental Medicine</i> , 2003, 198, 1023-1034.	8.5	196
40	Tumor-Derived Cytokines Dysregulate Macrophage Interferon- $\beta$ Responsiveness and Interferon Regulatory Factor-8 Expression. <i>Experimental Biology and Medicine</i> , 2003, 228, 270-277.	2.4	5
41	A male genital tract-specific carbohydrate epitope on human CD52: Implications for immunocontraception. <i>Tissue Antigens</i> , 2002, 60, 354-364.	1.0	20
42	Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. <i>Immunological Reviews</i> , 2002, 188, 136-146.	6.0	117
43	Manipulation of Avidity to Improve Effectiveness of Adoptively Transferred CD8+ T Cells for Melanoma Immunotherapy in Human MHC Class I-Transgenic Mice. <i>Journal of Immunology</i> , 2001, 167, 5824-5831.	0.8	79
44	Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice. <i>Journal of Immunology</i> , 2001, 167, 4853-4860.	0.8	48
45	Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen. <i>Journal of Experimental Medicine</i> , 2000, 191, 1221-1232.	8.5	154
46	Tumor growth modulates macrophage nitric oxide production following paclitaxel administration. <i>International Journal of Immunopharmacology</i> , 1998, 20, 537-551.	1.1	8
47	Interleukin-12 Overcomes Paclitaxel-Mediated Suppression of T-Cell Proliferation. <i>Immunopharmacology and Immunotoxicology</i> , 1998, 20, 473-492.	2.4	26
48	Tumor-induced immune dysfunction: the macrophage connection. <i>Journal of Leukocyte Biology</i> , 1998, 64, 275-290.	3.3	348
49	Taxol-mediated changes in fibrosarcoma-induced immune cell function: Modulation of antitumor activities. <i>Cancer Immunology, Immunotherapy</i> , 1997, 45, 20-28.	4.2	26
50	Taxol, a microtubule-stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production. <i>Immunopharmacology</i> , 1997, 37, 63-73.	2.0	24